Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS): Education for Healthcare Providers
Describe components of an effective treatment plan, such as treatment goals, patient interactions, and collaboration with the healthcare team
CME: 3.0
Optimizing Control in T2D: Part 2 in a Quality Improvement Program for Primary Care
Outline the benefits, indications, and role of continuous glucose monitoring (CGM) in optimizing glycemic control in patients with T2DM
CME: 1.0
Psoriasis Posters and Abstracts from San Diego
Summarize the latest research developments in the treatment of psoriasis and incorporate evidence-based research into clinical practice.
CME: 2.0
An Update on Tailored Feeding Strategies for Preterm Infants
Outline composition differences in enriched, fortified, and supplemented formulas and their impact on growth and development in preterm infants.
CME: 0.5
CVD AND RENAL DISEASE IN T2DM: Individualizing Therapeutic Options to Reduce Comorbid Risk
Utilize evidence-based recommendations to individualize pharmacologic treatment options for patients with T2DM
CME: 1.0
Managing Patients With Insomnia and Comorbid Conditions: Highlights From a SLEEP 2018 CME Symposium on Orexins
Incorporate evidence-based approaches to the management of patients with insomnia and comorbid conditions
CME: 0.75
Patient Case Study: Colin, 61-year-old, male, former smoker, with shortness of breath and a persistent cough
Complete this mystery patient case study by applying your knowledge to diagnose and treat Colin before it’s too late.
CME: 0.25
Expert Perspectives: The Why and How for Combination Basal Insulin + GLP-1RA Therapy in Type 2 Diabetes
Compare the benefits and limitations of GLP-1RA vs prandial insulin as add-on to basal insulin
CME: 1.5
Progress and Promise in the Identification and Management of Interstitial Lung Disease
Apply updated efficacy and safety data, recent guidelines, and individual patient characteristics, such as comorbidities, when making treatment decisions for patients with idiopathic pulmonary fibrosis.
CME: 0.5

Primary Care